Evidence map›Paper›PMID 41089852›Full record

ArticleFrontiers in pharmacology2025

Ning Yao, Xin Wang, Yajie Chen, Yunjuan Wu, Ying Su, Xinxin Su, Yajuan Geng, Xiaoning Liu, Limin Tian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ning YaoThe First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Xin WangCollege of Integrative Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Yajie ChenCollege of Integrative Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Yunjuan WuCollege of Integrative Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Ying SuCollege of Integrative Chinese and Western Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Xinxin SuThe First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Yajuan GengThe First School of Clinical Medicine, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Xiaoning LiuSchool of Public Health, Lanzhou University, Lanzhou, Gansu, China.
Limin TianDepartment of Endocrinology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Purpose: This study aimed to evaluate the therapeutic effects of Methods: Two-day-old male C57BL/6J mice were subcutaneously injected with streptozotocin (200 μg/20 μL per mouse). At 4 weeks of age, the mice were weaned and switched to a high-fat diet until week 9 to induce T2DM-related MASH. Starting from week 5, Results: Conclusion:

Indexed as

Coptidis rhizomaepiberberineIL-17RA/NF-κB signaling pathwaymetabolic dysfunction-associated steatohepatitistraditional Chinese medicinetype 2 diabetes mellitus

Identifiers

PMID41089852
PMCPMC12515859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.